Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma
The purpose of the present study was to detect the expression levels of circulating miR-148a in the peripheral blood of osteosarcoma patients and to further investigate the clinicopathological, diagnostic, and prognostic value of miR-148a. Eighty-nine patients with initially diagnosed osteosarcoma who successfully underwent surgical resection were enrolled in this prospective study. The expression levels of circulating miR-148a were detected by real-time quantitative RT-PCR. All statistical analyses were performed with SPSS 18.0 statistical software to determine the potential values of circulating miR-148a on the clinicopathological factors, diagnosis, and prognosis. The expression levels of circulating miR-148a in osteosarcoma patients were significantly higher than that in the healthy controls (P < 0.001), and miR-148a was capable of distinguishing osteosarcoma patients from healthy controls effectively (AUC = 0.783). In addition, miR-148a expression was significantly associated with tumor size (P = 0.049) and distant metastasis (P = 0.004). Univariate survival analysis demonstrated that patients with miR-148a high expression had significantly poor overall survival (P < 0.001) and disease-specific survival (P < 0.001) after 5 years’ operation. Multivariate survival analysis confirmed that miR-148a high expression was an independent predictor for unfavorable overall survival (P = 0.003) and disease-specific survival (P = 0.008), respectively. Our findings demonstrated that detection of circulating miR-148a expression in the peripheral blood have clinical potentials as an indicator of progressive phenotype, a novel diagnostic biomarker and a promising predictor to identify individuals with poor prognosis for osteosarcoma patients.
KeywordsCirculating miR-148a Diagnostic Prognostic biomarker Osteosarcoma
This work was supported by the grant from the Scientific Research Project of the Second Hospital of Shandong University (Y2013010054).
The authors were grateful toYuan Zhang (Department of Evidence-based medicine) for his technical guide and data analysis from the Second Hospital of Shandong University, Shandong University, China.
Conflicts of interest
- 12.Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotech. 2010;2:161–79.Google Scholar